The key to a successful outcome is early identification with individualized therapy and follow-up, with awareness of hematuria as the primary presenting symptom of the greatest importance.75, 76Fisetin altered the ratio of pro- and antiapoptotic proteins in human bladder cancer by upregulating p53 and downregulating NF-κB activation. The gene discussed is TP53; the disease is urinary bladder cancer.